Quality of life assessment in patients with chronic pancreatitis receiving antioxidant therapy

Table 1 Profile of patients with chronic pancreatitis matched for similar disease duration

	CP patients on Antox (n = 28)	CP patients NOT on Antox (n = 28)	P-value
Age (yr), median (range)	53 (24-82)	53 (31-74)	0.30 (Mann-Whitney U-test)
Etiologies	Alcohol: 13 (46%)	Alcohol: 17 (61%)
	Idiopathic: 13 (46%)	Idiopathic: 11 (39%)
	Others: 2 (8%)
Gender (male:female)	16:12	18:10	0.79 (Fisher’s exact test)
Duration of disease (yr), median (range)	8 (1-22)	7 (1-23)	0.85 (Mann-Whitney U-test)
Current cigarette smoking	8 (27%)	18 (62%)	0.01 (Fisher’s exact test)
Alcohol before diagnosis of CP	118 (48-240) g/d per person	160 (28-240) g/d per person	< 0.01 (Mann-Whitney U-test)
Alcohol intake, current mean (range)	25 (0-48) g/d per person	33 (0-96) g/d per person	0.63 (Mann-Whitney U-test)

CP: Chronic pancreatitis.

Table 2 Quality of life, pain scores and analgesic usage in disease duration-matched patients with chronic pancreatitis

	CP patients on Antox (n = 28)	CP patients NOT on Antox (n = 28)	P-value
Median visual analogue pain scores (range 0-10)	3 (0-8)	6 (0-8)	< 0.01 (Mann-Whitney U-test)
Patients taking analgesics	16	26	< 0.01
Patients taking opiate analgesics	11	23	< 0.01
Diabetes	10 (36%)	11 (39%)	0.80
Pancreatic exocrine supplements	14 (50%)	16 (57%)	0.60

CP: Chronic pancreatitis.

Table 3 Detailed European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core questions 30 and Pancreatic Modification (28 questions) results in disease duration-matched patients with chronic pancreatitis

Scales	Items	CP patients on Antox mean score (n = 28)	CP patients NOT on Antox mean score (n = 28)	P-value	95% CI
Physical Functioning	Q-1-5	1.5	1.97	0.0051	-0.8 to 0.1
Role Functioning	Q-6-7	1.84	2.75	0.0011	-1.5 to 0.5
Pain	Q-9, 19	2.1	3.1	< 0.00011	-1.5 to 0.7
Fatigue	Q-10, 12, 18	2.05	2.86	0.00011	-1.7 to 0.3
Nausea and vomiting	Q-14, 15	1.5	2.2	0.0021	-1.2 to 0.2
Cognitive functioning	Q-20, 25	1.6	2.4	< 0.00011	-1 to 0.5
Emotional functioning	Q-21-24	1.8	2.6	0.00071	-1.2 to 0.5
Social functioning	Q-26, 27	1.8	2.7	0.00321	-1.2 to 0.2
Global quality of life	Q-29, 30	2.6	4.9	< 0.00011	1.5 to 3
Pancreatic Pain	Q-31, 33, 35	1.9	2.9	< 0.00011	-1.5 to -0.7
Digestive function	Q-36, 37	2.14	2.5	0.091	-1 to 0
Jaundice	Q-44, 45	1.1	1.2	0.411	-0.25 to 0
Altered bowel functioning	Q-46, 47	2.1	1.6	0.071	-1 to 0
Body Image	Q-48, 51	1.3	2.5	0.00041	-1.2 to -0.25
Alcohol related guilt	Q-49, 50	1.5	1.4	0.71	-0.25 to 0.5
Satisfaction with health care	Q-55, 56	3.2	3.4	0.441	-0.5 to 0.25
Sexual functioning	Q-57, 58	1.7	2.66	0.00031	-1.5 to -0.5
Dyspnea/shortness of breath	Q-8	1.5	1.6	0.631	-0.5 to 0
Difficulty sleeping	Q-11	1.9	2.9	0.00031	-1.5 to 0.5
Loss of appetite	Q-13	1.8	2.5	0.041	-1.5 to 0
Constipation	Q-16	1.7	1.8	0.862	-1 to 0.5
Diarrhea	Q-17	1.5	1.5	0.032	-1 to 0
Financial problems	Q-28	1.3	1.9	0.022	-1 to 0
Bloated abdomen	Q-32	1.9	2.8	0.0022	-1.5 to 0.5
Night pain	Q-34	1.8	3.1	< 0.00012	-2 to -0.5
Taste changes	Q-38	1.2	1.7	0.022	-1 to 0
Indigestion	Q-39	1.7	2.4	0.0182	-1 to 0
Flatulence	Q-40	2.0	2.6	0.062	-1 to 0
Weight loss	Q-41	1.2	2.4	< 0.00012	-1.5 to -0.5
Decreased muscle strength	Q-42	1.8	2.3	0.112	-1 to 0
Dry mouth	Q-43	1.6	2.2	0.022	-1 to 0
Treatment side effects	Q-52	1.2	2.0	0.00022	-1 to -0.5
Fear for future health	Q-53	2.4	3.0	0.032	-1 to 0
Ability to plan ahead	Q-54	1.8	2.9	0.00012	-1.5 to 0.5

¹Wilcoxon signed rank test 95% CI;

²Wilcoxon t-test. CP: Chronic pancreatitis; Q: Question No. (total C-30 + PAN 28 = 58 questions).